Larimar Therapeutics names John B. Harlow Jr. president and COO
The board's appointment, effective September 29, 2026, comes with a $560,000 base salary, a $35,000 signing bonus, and inducement equity grants.
SEC filing
Latest
4 stories
Tuesday, September 29
Wednesday, September 9
Century Therapeutics adds Joseph Truitt to board of directors
The iPSC-derived cell therapy company appointed the iECURE CEO effective September 9, 2026, expanding its board to seven members.
SEC filing
Friday, August 21
Larimar registers Phase 3 FORWARD-FA trial of nomlabofusp for Friedreich's ataxia
Tuesday, August 4
Larimar reports Q2 2026 update on nomlabofusp BLA, Phase 3 timing and cash
Larimar says FDA aligned on a rolling BLA path for nomlabofusp in Friedreich's ataxia and expects to start a global confirmatory Phase 3 study in the third quarter of 2026.
SEC filing